Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy

Clinical Therapeutics

Volumn 27, Issue 5, 2005, Pages 618-626

  Carlsson, Kristin Cecilie ^a   Hoem, Nils Ove ^a   Glauser, Tracy ^b   Vinks, Alexander A ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Carbamazepine; Drug monitoring; Epilepsy; Pediatrics; Pharmacokinetics

Indexed keywords

CARBAMAZEPINE;

ACCURACY; ADULT; ALGORITHM; ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT; POPULATION MODEL; STATISTICAL MODEL; STEADY STATE;

ADOLESCENT; ADULT; ANTICONVULSANTS; BAYES THEOREM; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; EPILEPSY; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL;

EID: 20644437743     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.05.001     Document Type: Article

References (34)

1. Johannessen SI, Battino D, and Berry DJ Therapeutic drug monitoring of the newer antiepileptic drugs Ther Drug Monit 25 2003 347 363
2. Hartley R, Forsythe WI, and McLain B Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children Clin Pharmacokinet 20 1991 237 246
3. Beardsley RS, Freeman JM, and Appel FA Anticonvulsant serum levels are useful only if the physician appropriately uses them: An assessment of the impact of providing serum level data to physicians Epilepsia 24 1983 330 335
4. Perucca E Overtreatment in epilepsy: Adverse consequences and mechanisms Epilepsy Res 52 2002 25 33
5. Jelliffe RW, Schumitzky A, and Van Guilder M User Manual for Version 10.7 of the USC* (*)PACK Collection of PC Programs 1995 University of Southern California Los Angeles, Calif
6. Proost JH, and Meijer DK MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring Comput Biol Med 22 1992 155 163
7. Eadie MJ Therapeutic drug monitoring-antiepileptic drugs Br J Clin Pharmacol 46 1998 185 193
8. Monaco F, Riccio A, and Benna P Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effects Neurology 26 1976 936 973
9. Strandjord RE, and Johannessen SI Single-drug therapy with carbamazepine in patients with epilepsy: Serum levels and clinical effect Epilepsia 21 1980 655 662
10. Larkin JG, Herrick AL, and McGuire GM Antiepileptic drug monitoring at the epilepsy clinic: A prospective evaluation Epilepsia 32 1991 89 95
11. Callaghan N, O'Callaghan M, Duggan B, and Feely M Carbamazepine as a single drug in the treatment of epilepsy. A prospective study of serum levels and seizure control J Neurol Neurosurg Psychiatry 41 1978 907 912
12. McNamara JO Drugs effective in the therapy of the epilepsies Hardman JG Limbird LE Goodman & Gilman's The Pharmacological Basis of Therapeutics 9th ed. 1996 McGraw-Hill New York 473 475
13. Levy RH, Pitlick WH, and Troupin AS Pharmacokinetics of carbamazepine in normal man Clin Pharmacol Ther 17 1975 657 668
14. Pynnonen S, Mantyla R, and Iisalo E Bioavailability of four different pharmaceutical preparations of carbamazepine Acta Pharmacol Toxicol (Copenh) 43 1978 306 310
15. Konsil J, Dechasathian S, Mason DH Jr, and Stevens RE Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation J Pharm Pharma Sci 5 2002 169 175
16. Bertilsson L, Hojer B, and Tybring G Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique Clin Pharmacol Ther 27 1980 83 88
17. Almeida AM, Falcao AC, and Sales F Kinetic profile of carbamazepine in an adult Portuguese outpatient population J Clin Pharm Ther 23 1998 315 321
18. Chan E, Lee HS, and Hue SS Population pharmacokinetics of carbamazepine in Singapore epileptic patients Br J Clin Pharmacol 51 2001 567 576
19. Deleu D, Aarons L, and Ahmed IA Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients Eur J Clin Pharmacol 57 2001 243 248
20. El Desoky ES, and Kandil MR Bayesian estimation of six different sets of carbamazepine pharmacokinetic parameters in Egyptian adult epileptic patients Pharmacol Res 45 2002 113 118
21. Miller R, and Ludden TM Bioavailability of controlled release carbamazepine estimated by mixed effect modelling Eur J Clin Pharmacol 44 1993 231 235
22. Bondareva IB, Sokolov AV, Tischenkova IF, and Jelliffe RW Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: Implications for dosage J Clin Pharm Ther 26 2001 213 223
23. Jelliffe RW Explicit determination of laboratory assay error patterns-a useful aid in therapeutic drug monitoring (TDM) Check Sample Series, Drug Monitoring and Toxicology 10 1990 American Society of Clinical Pathologists Continuing Education Program Chicago, Ill 1 6
24. Sheiner LB, and Beal SL Some suggestions for measuring predictive performance J Pharmacokinet Biopharm 9 1981 503 512
25. SAAM II User Guide. Version 1.1.1 1997 SAAM Institute, Inc Seattle, Wash
26. Summers B, and Summers RS Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication Clin Pharmacokinet 17 1989 208 216
27. Peytchev L, and Chakova L Comparative drug monitoring of carbamazepin suspension (TroyaPharm) and Tegretol syrup (Ciba Geigy) in epileptic children Folia Med (Plovdiv) 40 1998 29 33
28. Cotter LM, Smith G, and Hooper WD The bioavailability of carbamazepine Proc Aust Assoc Neurol 12 1975 123 128
29. Faigle JW, and Feldmann KF Pharmacokinetic data of carbamazepine and its major metabolites in man Schneider H Janz D Gardner-Thorpe C Clinical Pharmacology of Anti-Epileptic Drugs 1975 Springer-Verlag Berlin 159 165
30. 15N-labelled drug to healthy volunteers Br J Clin Pharmacol 32 1991 573 579
31. Thakker KM, Mangat S, and Garnett WR Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients Biopharm Drug Dispos 13 1992 559 569
32. [published correction appears in JAMA. 1989;262:1472] Cramer JA, Mattson RH, and Prevey ML How often is medication taken as prescribed? A novel assessment technique JAMA 261 1989 3273 3277
33. Falcao AC, de Almeida AM, and Leitao F Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population Ther Drug Monit 21 1999 224 230
34. D'Argenio DZ Optimal sampling times for pharmacokinetic experiments J Pharmacokinet Biopharm 9 1981 739 756